Eloxx Pharmaceuticals, Inc. balance sheet ELOX

Annual Quarterly

As of Jun 30, 2026, Eloxx Pharmaceuticals, Inc. had total assets of $63.4 million. Stockholders' equity was $46.4 million. It held $62.0 million in cash and investments against $0 of total debt, net cash of $62.0 million. The current ratio, current assets divided by current liabilities, was 3.74.

USD in millions, except ratios and per-share amounts. The percent under a figure is the change from the year before.

Line	FY 2026 Jun 30, 2026	FY 2025 Dec 31, 2025	FY 2022 Dec 31, 2022	FY 2021 Dec 31, 2021	FY 2020 Dec 31, 2020	FY 2019 Dec 31, 2019	FY 2018 Dec 31, 2018	FY 2017 Dec 31, 2017	FY 2017 Jun 30, 2017	FY 2016 Jun 30, 2016	FY 2015 Jun 30, 2015
Assets
Cash	62	5	19 -54.6%	42 +71.3%	25 +9.7%	22 -53.7%	49 +146312.4%	24 +2866.1%	0 -95.9%	1 -75.7%	3 -45.4%
Short-term investments	—	—	—	—	—	34	—	—	—	—	—
Cash and investments	62	5	19 -54.6%	42 -27.7%	25 +9.7%	56 +15.8%	49 +146312.4%	24 +2866.1%	0 -95.9%	1 -75.7%	3 -45.4%
Receivables	—	—	—	—	—	—	—	—	—	—	0 -100.0%
Total current assets	63	5	20 -53.7%	43 +67.9%	26 -55.1%	58 +14.6%	50 +17599.5%	25 +2393.9%	0 -71.1%	1 -73.7%	4 -48.4%
Property and equipment, net	—	0	0 -21.8%	0 +62.4%	0 -33.8%	0 -19.0%	0 +386.5%	0 +200.4%	0 -44.9%	0 -50.2%	0 -16.8%
Goodwill	—	—	—	—	—	—	—	—	—	0 -100.0%	6 -58.4%
Total assets	63	5	21 -53.2%	45 +70.5%	26 -55.1%	59 +16.2%	51 +767.7%	25 +168.6%	6 -36.6%	9 -52.8%	20 -41.4%
Liabilities and equity
Accounts payable	3	3	3 +119.0%	1 +186.7%	0 -74.3%	2 +150.5%	1 +289.9%	2 +1594.3%	0 +112.2%	0 -61.1%	0 -74.3%
Total current liabilities	17	17	23 +132.0%	10 +1.2%	10 -16.7%	12 +51.2%	8 +181.4%	3 +827.7%	3 +651.8%	0 -52.6%	1 -57.3%
Total liabilities	—	17	32 +39.7%	23 +40.1%	16 -28.5%	23	—	—	5 +6.6%	5 -36.3%	7 +25.3%
Stockholders' equity	46	-12	-11 -147.6%	22 +118.8%	10 -71.8%	36 -15.6%	43 +4825.5%	21 +368.4%	1 -80.9%	5 -62.7%	12 -55.5%
Debt
Debt due within a year	0	1	4 -24.0%	—	5 +20.8%	4	—	—	—	—	—
Long-term debt	—	0	9 -28.7%	12 +88.1%	6 -39.3%	11	—	—	—	—	—
Lease liabilities	—	0	1 -42.0%	1 +246.2%	0 -54.3%	1	—	—	—	—	—
Total debt	0	1	13 -28.4%	13 +20.8%	12 -23.6%	16	—	—	—	—	—
Net cash	62	4	6 -75.3%	29 -39.1%	13 +87.7%	41	—	—	—	—	—
Ratios
Current ratio	3.74x	0.31x	0.87x	4.37x	2.63x	4.89x	6.45x	7.16x	0.10x	2.66x	4.79x
Debt to equity	0.00x	—	—	0.60x	1.18x	0.44x	—	—	—	—	—
Return on equity	—	—	—	-298.10%	-338.00%	-140.49%	-109.96%	-99.31%	-2,435.02%	-181.29%	-147.76%
Return on assets	—	-113.76%	-170.74%	-147.83%	-130.59%	-86.30%	-93.03%	-85.60%	-362.93%	-89.62%	-92.41%
Book value per share	11.50	-27.35	-4.92	10.33	0.25	0.90	1.20	0.78	0.03	0.22	0.65

How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except ratios and per-share amounts. Cash and investments adds short-term and long-term marketable securities to cash. Debt due within a year is the borrowings that are not already in long-term debt. Total debt is those borrowings plus lease liabilities. Net cash is cash and investments minus total debt. Return on equity and return on assets divide the trailing twelve months of net income by the balance on that date. Debt to EBITDA uses the trailing twelve months of EBITDA. The first column is the latest balance sheet when it is newer than the latest fiscal year. More on our methodology.

Company profile

Industry: Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as: ELOX (Nasdaq)
Fiscal year ends: December 31
Incorporated in: DE
Headquarters: Arlington, MA
SEC filer status: Non-accelerated filer, Smaller reporting company
SEC CIK: 1035354
Former names: Sevion Therapeutics, Inc. (until Dec 22, 2017); SENESCO TECHNOLOGIES INC (until Sep 29, 2014); NAVA LEISURE USA INC (until May 24, 1999)

Other Biological Products, (No Diagnostic Substances) companies

All 182 Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.